Health & Biotech Copy RSS link Link copied to clipboard!
Citi raises AstraZeneca earnings forecast citing pipeline momentum
Citi has raised its earnings forecast for AstraZeneca PLC, maintaining a constructive outlook ahead of key late-stage clinical catalysts expected later in the year. The analyst upgrade reflects improved earnings expectations driven by consistent performance in oncology, cardiovascular, respiratory, and rare disease segments. Market attention remains focused on upcoming data releases from the company's diversified therapeutic pipeline, which supports long-term visibility and operational stability within the global healthcare sector.
Clinical-stage biotechnology market forecast to reach $97.12 billion by 2030
The clinical-stage biotechnology market is projected to grow at a compound annual growth rate of 15.5%, reaching a valuation of $97.12 billion by 2030. Key drivers include increased investment in late-stage trials, demand for innovative therapeutics, and the adoption of digital tools. The market is segmented by product type, development phase, application areas, and end-users. Notable developments include BioNTech SE's acquisition of CureVac N.V. in June 2025 and Ichor Life Sciences Inc.'s launch of clinical trial services in November 2023. Major players include Sarepta Therapeutics Inc., PTC Therapeutics Inc., and Evotec SE.
EMA pilot programme for breakthrough medical devices applications open
The European Medicines Agency (EMA) has opened applications for its pilot programme providing expert panel advice for developers of breakthrough medical devices and in vitro diagnostic medical devices. The first phase, targeting Class III and Class IIb active devices, accepts submissions until 22 May 2026, with a focus on cardiovascular and paediatric devices. Five applications will be selected for initial assessment. The programme aims to test adaptive certification procedures proposed in the revision of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).